DexCom (DXCM) Projected to Announce Earnings on Thursday

DexCom (NASDAQ:DXCM) is expected to post its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $0.61 per share and revenue of $1.2903 billion for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period last year, the firm earned $0.32 earnings per share. DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, analysts expect DexCom to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

DexCom Price Performance

Shares of DexCom stock opened at $74.85 on Wednesday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $28.88 billion, a price-to-earnings ratio of 31.99, a price-to-earnings-growth ratio of 1.21 and a beta of 1.45. DexCom has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a 50-day simple moving average of $72.79 and a two-hundred day simple moving average of $69.01.

Insider Activity

In other news, EVP Jon Coleman sold 4,911 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the sale, the director owned 52,852 shares in the company, valued at $3,917,918.76. This represents a 7.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 98,506 shares of company stock valued at $7,205,258. Company insiders own 0.28% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC raised its stake in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares in the last quarter. Empowered Funds LLC raised its stake in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after acquiring an additional 436 shares in the last quarter. Focus Partners Wealth lifted its holdings in shares of DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after acquiring an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of DexCom by 1.4% in the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after acquiring an additional 258 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. UBS Group set a $96.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Tuesday. Robert W. Baird set a $80.00 price target on DexCom in a research note on Friday, May 1st. Stifel Nicolaus set a $90.00 price target on DexCom and gave the company a “buy” rating in a research note on Friday, June 5th. Sanford C. Bernstein set a $77.00 price target on DexCom in a research report on Friday, May 1st. Finally, Piper Sandler restated an “overweight” rating and set a $88.00 price objective (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.40.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.